We are live on ! Find out more
NMTC icon

NeuroOne Medical Technologies

0.6521 USD
-0.0228
3.38%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
0.6521
0.0000
0%
1 day
-3.38%
5 days
-14.2%
1 month
-33.72%
3 months
-69.67%
6 months
-84.06%
Year to date
-87.24%
1 year
-81.94%
5 years
-95.21%
10 years
-98.5%
 

About: NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.

Employees: 18

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
24 days ago
NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System
Study Reports Immediate Pain Freedom in 14 of 15 Patients; all Patients Achieved Favorable Pain Outcomes at a Mean Six-Month Follow-Up Multi-Contact Probe Technology Enabled Mapping and Treatment of Trigeminal Nerve Distributions without Repeated Probe Repositioning EDEN PRAIRIE, Minn., Oct. 29, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on the surgical diagnosis and treatment of neurological disorders, today announced the publication of initial clinical results evaluating its OneRF® Trigeminal Nerve Ablation System in the peer-reviewed journal Pain Management.
NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System
Neutral
GlobeNewsWire
26 days ago
NeuroOne Featured in New York Post on OneRF® Patient's Remarkable Journey to Overcome Debilitating Facial Pain
NeuroOne's FDA 510(k)-Cleared OneRF Trigeminal Nerve Ablation System Offers Hope for Patients Suffering from Trigeminal Neuralgia EDEN PRAIRIE, Minn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today highlighted a feature article published in the New York Post showcasing the successful treatment of a patient* suffering from trigeminal neuralgia, a debilitating neurological condition, using the Company's FDA 510(k)-cleared OneRF® Trigeminal Nerve Ablation System.
NeuroOne Featured in New York Post on OneRF® Patient's Remarkable Journey to Overcome Debilitating Facial Pain
Neutral
GlobeNewsWire
1 month ago
NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program
NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Research
NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program
Neutral
GlobeNewsWire
1 month ago
NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology
New NIH Award will Initially Provide NeuroOne Approximately $200,000 through April 2027 EDEN PRAIRIE, Minn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced it has entered into a research and development subaward agreement with Dartmouth to support the advancement of next-generation neurotransmitter sensing technology.
NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology
Neutral
GlobeNewsWire
1 month ago
NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September 30, 2026, and provided an update on recent product orders.
NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
Neutral
GlobeNewsWire
2 months ago
NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement
EDEN PRAIRIE, Minn., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on transforming the surgical diagnosis and treatment of neurological disorders, today announced a new Southern California distribution agreement for its FDA-cleared OneRF® Trigeminal Nerve Ablation System.
NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement
Neutral
Seeking Alpha
3 months ago
NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript
Neutral
Seeking Alpha
6 months ago
NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript
Neutral
Seeking Alpha
8 months ago
NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript
NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript
NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript
Neutral
Seeking Alpha
9 months ago
NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript
Price charts implemented using Lightweight Charts™